Share on StockTwits

Research analysts at Argus lowered their price target on shares of GlaxoSmithKline plc (NYSE:GSK) from $65.00 to $55.00 in a report released on Friday. The firm currently has a “buy” rating on the stock. Argus’ price objective suggests a potential upside of 18.66% from the stock’s previous close.

GSK has been the subject of a number of other recent research reports. Analysts at Galvan Research reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday. Separately, analysts at Mainfirst downgraded shares of GlaxoSmithKline plc to an “underperform” rating in a research note on Monday, July 28th. Finally, analysts at Bank of America downgraded shares of GlaxoSmithKline plc from a “buy” rating to a “neutral” rating in a research note on Monday, July 28th. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating to the company’s stock. GlaxoSmithKline plc currently has an average rating of “Hold” and a consensus price target of $52.67.

GlaxoSmithKline plc (NYSE:GSK) opened at 46.35 on Friday. GlaxoSmithKline plc has a one year low of $46.22 and a one year high of $56.73. The stock has a 50-day moving average of $51.94 and a 200-day moving average of $53.68. The company has a market cap of $111.3 billion and a price-to-earnings ratio of 14.60.

GlaxoSmithKline plc (NYSE:GSK) last released its earnings data on Wednesday, July 23rd. The company reported $0.65 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.71 by $0.06. Analysts expect that GlaxoSmithKline plc will post $3.34 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Thursday, October 2nd. Shareholders of record on Friday, August 8th will be paid a dividend of $0.6482 per share. This represents a $2.59 annualized dividend and a dividend yield of 5.59%. The ex-dividend date is Wednesday, August 6th.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Receive News & Ratings for GlaxoSmithKline plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.